DebioPharm has launched its gonadotropin releasing hormone (GnRH) agonist analogue Salvacyl (extended-release triptorelin), for the treatment of sexual deviancy by the reversible reduction of serum testosterone to castrate levels, in Germany and Belgium.
DebioPharm's Salvacyl launched in EU for sexual deviancy
DebioPharm has launched its gonadotropin releasing hormone (GnRH) agonist analogue Salvacyl (extended-release triptorelin), for the treatment of sexual deviancy by the reversible reduction of serum testosterone to castrate levels, in Germany and Belgium.